{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:19Z","timestamp":1790352559702,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Zolbetuximab for CLDN18.2-positive advanced gastric cancer frequently causes chemotherapy-induced nausea and vomiting (CINV), particularly during the first infusion. Single-center studies in Japan have reported standardized infusion protocols and antiemetic strategies; however, these uniform approaches do not allow evaluation of how differences in infusion rate settings, antiemetic combinations, or patient backgrounds influence CINV. Using real-world data from multiple institutions with various clinical practices, the aim of this study was to clarify factors associated with CINV during the first zolbetuximab infusion, focusing on infusion rate, antiemetic use, and patient characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter retrospective study included patients with CLDN18.2-positive unresectable or recurrent gastric cancer who received zolbetuximab between June 2024 and April 2025. Clinical characteristics, gastrectomy status, infusion parameters, antiemetic use, and CINV events during the first infusion were extracted from electronic medical records. CINV severity was assessed using CTCAE or patient-reported scales (NRS and Faces Scale), depending on institutional practice. Accordingly, CTCAE Grade\u2009\u2265\u20092, NRS\u2009\u2265\u20093, or Faces Scale\u2009\u2265\u20096 were defined as moderate-or-greater nausea. Patient backgrounds were summarized using descriptive statistics. Associations between CINV and age group, sex, gastrectomy status, antiemetic combinations, and infusion-rate categories were evaluated with exploratory analyses using Fisher\u2019s exact or \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-four patients were analyzed. CINV during the first zolbetuximab infusion was more frequent in patients without gastrectomy (38.7%) than in those with gastrectomy (7.7%). Younger age was associated with increased risk, whereas sex differences were minimal. Olanzapine use reduced the incidence of moderate-or-greater nausea or any-grade vomiting (18.2% vs 32.4%). CINV typically occurred when infusion rates reached approximately 200\u2013250\u2009mg\/h, suggesting an increased risk when rates exceeded approximately 150\u2009mg\/h. Combined risk analysis showed that gastrectomy status had a stronger influence on CINV than age or sex, and olanzapine further reduced risk among non-gastrectomized patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Infusion-phase CINV during the first zolbetuximab infusion was associated with both patient-related and administration-related factors in real-world practice. Quantitative evaluation of infusion-rate ranges and the influence of gastric mucosal status suggest that nausea severity may be partially modifiable through optimized infusion management and risk-adapted antiemetic strategies. These exploratory findings warrant prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00569-z","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:49:21Z","timestamp":1775490561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidence and clinical characteristics of zolbetuximab-induced nausea and vomiting in CLDN18.2-positive unresectable advanced or recurrent gastric cancer: a retrospective study"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8166-8165","authenticated-orcid":false,"given":"Yosuke","family":"Ando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Banno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoe","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Katsuragawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Kumazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"569_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"key":"569_CR2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"key":"569_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10120-025-01607-9","volume":"28","author":"Y Sugiyama","year":"2025","unstructured":"Sugiyama Y, Tanabe H, Tachibana S, Iribe K, Yuzawa S, Iwaki H, et al. Zolbetuximab-related gastritis: a case report of the patient with prolonged gastrointestinal symptoms. Gastric Cancer. 2025;28:705\u201311. https:\/\/doi.org\/10.1007\/s10120-025-01607-9.","journal-title":"Gastric Cancer"},{"key":"569_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jphs.2024.08.005","volume":"156","author":"F Kinugasa","year":"2024","unstructured":"Kinugasa F, Kajikawa S, Weng J, Ugawa T, Fushiki H, Yamanaka Y, et al. Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets. J Pharmacol Sci. 2024;156:161\u201370. https:\/\/doi.org\/10.1016\/j.jphs.2024.08.005.","journal-title":"J Pharmacol Sci"},{"key":"569_CR5","doi-asserted-by":"publisher","first-page":"100128","DOI":"10.1016\/j.esmogo.2024.100128","volume":"7","author":"K Shimozaki","year":"2025","unstructured":"Shimozaki K, Ooki A, Yamahata Y, Aoyama T, Yoshino K, Tamba M, et al. Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice. ESMO Gastrointest Oncol. 2025;7:100128. https:\/\/doi.org\/10.1016\/j.esmogo.2024.100128.","journal-title":"ESMO Gastrointest Oncol"},{"key":"569_CR6","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3390\/cancers17121996","volume":"17","author":"Y Narita","year":"1996","unstructured":"Narita Y, Mizuno T, Suda T, Kurono J, Ishizuka Y, Iida Y, et al. Practical management of zolbetuximab administration. The project VYLOY initiative. Cancers (Basel). 1996;17:2025. https:\/\/doi.org\/10.3390\/cancers17121996.","journal-title":"Cancers (Basel)"},{"key":"569_CR7","doi-asserted-by":"publisher","unstructured":"Yakuwa E, Shoji Y, Oizumi T, Kobayashi Y, Motoishi T, Katagiri T, et al. Safety and feasibility of outpatient zolbetuximab administration in community cancer care: a mixed-methods analysis. in vivo. Vol. 39. Athens, Greece; 2025. p. 951\u201360. https:\/\/doi.org\/10.21873\/invivo.13900.","DOI":"10.21873\/invivo.13900"},{"key":"569_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2020.00329","volume":"11","author":"ASM Mosa","year":"2020","unstructured":"Mosa ASM, Hossain AM, Lavoie BJ, Yoo I. Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol. 2020;11:329. https:\/\/doi.org\/10.3389\/fphar.2020.00329.","journal-title":"Front Pharmacol"},{"key":"569_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10147-015-0908-2","volume":"21","author":"H Iihara","year":"2016","unstructured":"Iihara H, Fujii H, Yoshimi C, Yamada M, Suzuki A, Matsuhashi N, et al. Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy. Int J Clin Oncol. 2016;21:409\u201318. https:\/\/doi.org\/10.1007\/s10147-015-0908-2.","journal-title":"Int J Clin Oncol"},{"key":"569_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/jocn.14705","volume":"28","author":"L Wikstr\u00f6m","year":"2019","unstructured":"Wikstr\u00f6m L, Nilsson M, Brostr\u00f6m A, Eriksson K. Patients\u2019 self-reported nausea: validation of the Numerical Rating Scale and of a daily summary of repeated Numerical Rating Scale scores. J Clin Nurs. 2019;28:959\u201368. https:\/\/doi.org\/10.1111\/jocn.14705.","journal-title":"J Clin Nurs"},{"key":"569_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/acem.12685","volume":"22","author":"R Meek","year":"2015","unstructured":"Meek R, Egerton-Warburton D, Mee MJ, Braitberg G. Measurement and monitoring of nausea severity in emergency department patients: a comparison of scales and exploration of treatment efficacy outcome measures. Acad Emerg Med. 2015;22:685\u201393. https:\/\/doi.org\/10.1111\/acem.12685.","journal-title":"Acad Emerg Med"},{"key":"569_CR12","unstructured":"Foundation W-BF. Wong-Baker FACES\u00ae Pain Rating Scale. https:\/\/wongbakerfaces.org\/. 12 Dec 2025."},{"key":"569_CR13","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1007\/s00520-016-3080-y","volume":"24","author":"L Kottschade","year":"2016","unstructured":"Kottschade L, Novotny P, Lyss A, Mazurczak M, Loprinzi C, Barton D. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (alliance). Support Care Cancer. 2016;24:2661\u201367. https:\/\/doi.org\/10.1007\/s00520-016-3080-y.","journal-title":"Support Care Cancer"},{"key":"569_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jpainsymman.2012.06.007","volume":"45","author":"WH Oldenmenger","year":"2013","unstructured":"Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CCD. Cut points on 0-e10 numeric rating scales for symptoms included in the Edmonton symptom assessment Scale in cancer patients: a systematic review. J Pain Symptom Manage. 2013;45:1083\u201393. https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.06.007.","journal-title":"J Pain Symptom Manage"},{"key":"569_CR15","unstructured":"Hokkaido Cancer Center. Bilroy\u00ae administration manual. 2025. Available from: https:\/\/hokkaido-cc.hosp.go.jp\/files\/000242129.pdf. 11 Feb 2026. 2nd ed. Hokkaido Cancer Center."},{"key":"569_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2019","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncol. 2019;21:242\u201349. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3.","journal-title":"The Lancet Oncol"},{"key":"569_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1515725.","journal-title":"N Engl J Med"},{"key":"569_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.breast.2020.01.005","volume":"50","author":"W Yeo","year":"2020","unstructured":"Yeo W, Lau TK, Li L, Lai KT, Pang E, Cheung M, et al. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. Breast. 2020;50:30\u201338. https:\/\/doi.org\/10.1016\/j.breast.2020.01.005.","journal-title":"Breast"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00569-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00569-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00569-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:32:35Z","timestamp":1781645555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00569-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00569-z","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Review Board of Fujita Health University (Approval Number: HM25-065), as well as by the institutional review boards of all participating collaborating institutions. All procedures involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Declaration of Helsinki, as revised in 2013, or with comparable ethical standards. Because of the retrospective nature of the study, the requirement for written informed consent was waived by the respective ethics committees. Instead, an opt-out approach was implemented by publicly disclosing study information on the websites of the participating institutions where patient enrollment was conducted, thereby providing eligible patients with the opportunity to refuse participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}